September 3, 2009 {QB3) qed@qb3-UCSF, Entrepreneurs' Luncheon Seminar

Dr. George Miljanich has been developing ion channel therapeutics, analgesics, and peptide-based therapeutics for more than 20 years.  As CEO at AIRMID, he leads the development of T-cell potassium channel blockers to treat autoimmune disorders.  Prior to AIRMID, he was Senior  Director  at Elan Pharmaceuticals, playing a key role in the clinical development, regulatory approval, and commercialization of the analgesic, PRIALT® (ziconotide.) Dr. Miljanich holds a BS and PhD in Chemistry from UC Berkeley and UC Santa Cruz,  respectively, and conducted post-doctoral research at UCSF with Prof. Regis Kelly. On the faculty at USC, he studied calcium channels and channel-blocking conotoxins.  Dr. Miljanich then moved to Neurex Corp. to translate these conotoxins into pharmaceuticals, contributing to the development of PRIALT from invention through Phase III trials.  With the acquisition of Neurex, he became head of analgesia research at Elan. Dr. Miljanich has authored numerous scientific publications and is an inventor on 15 U.S. patents.  He serves as a consultant to the pharmaceutical industry, is Vice President of the Toxinomics Foundation, and a member of the CONCO initiative.  The Foundation fosters development of toxin-based therapeutics and CONCO is a $12 million EU-based program for discovering and developing drugs from animal toxins.

Lunch provided, but space is limited so please reserve a seat at http://www.acteva.com/booking.cfm?bevaID=175891